5 mins | 30 mins | Hourly | Daily | Weekly |
---|---|---|---|---|
SELL | SELL | SELL | SELL | BUY |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MA5 | 2.92▼ | 2.92▼ | 2.91▲ | 2.96▼ | 2.87▼ |
MA10 | 2.91▲ | 2.93▼ | 2.96▼ | 2.92▼ | 2.67▲ |
MA20 | 2.96▼ | 2.99▼ | 3.02▼ | 2.92▼ | 2.73▲ |
MA50 | 3.01▼ | 2.99▼ | 2.97▼ | 2.61▲ | N/A |
MA100 | 2.97▼ | 2.94▼ | 2.80▲ | 2.78▲ | N/A |
MA200 | 2.72▲ | 2.65▲ | 2.56▲ | N/A | N/A |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MACD | -0.004▼ | -0.013▼ | -0.023▼ | -0.020▼ | N/A |
RSI | 40.335▼ | 41.723▼ | 42.551▼ | 49.805▼ | 51.227▲ |
STOCH | 29.293 | 14.941▼ | 4.131▼ | 41.655 | 76.566 |
WILL %R | -87.879▼ | -88.889▼ | -92.157▼ | -85.106▼ | -29.677 |
CCI | -32.331 | -49.612 | -74.534 | -55.122 | 88.393 |
Friday, June 13, 2025 06:17 AM
Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being ...
|
Monday, June 09, 2025 05:00 PM
NDA Submission Anticipated Q2 Calendar 2025PRINCETON, N.J., April 09, 2025 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage ...
|
Thursday, June 05, 2025 07:20 AM
GRCE READ THE FULL GRCE RESEARCH REPORT Grace Therapeutics, Inc (NASDAQ:GRCE) will soon submit its new drug application (NDA) to the FDA, which we expect in the next few weeks. The company recently ...
|
date | open | high | low | close | volume |
---|---|---|---|---|---|
13/06/25 | 2.86 | 2.98 | 2.80 | 2.84 | 35,100 |
12/06/25 | 2.87 | 2.96 | 2.87 | 2.92 | 41,200 |
11/06/25 | 3.02 | 3.10 | 2.85 | 2.85 | 124,400 |
10/06/25 | 3.12 | 3.165 | 3.01 | 3.01 | 87,755 |
09/06/25 | 2.95 | 3.30 | 2.95 | 3.16 | 137,522 |
06/06/25 | 2.98 | 3.00 | 2.96 | 2.97 | 16,700 |
05/06/25 | 2.92 | 2.98 | 2.88 | 2.96 | 13,411 |
04/06/25 | 2.80 | 2.99 | 2.80 | 2.88 | 36,477 |
03/06/25 | 2.88 | 2.9558 | 2.8001 | 2.82 | 17,616 |
02/06/25 | 2.77 | 2.8462 | 2.7595 | 2.81 | 6,594 |
|
|
||||
|
|
||||
|
|